Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. 
High-throughput analyses have revealed the presence of activating mutations in the AKT1 gene in a subpopulation of meningiomas.  We report a female patient with multiple intracranial tumor manifestations and histologically verified meningotheliomatous meningioma in the lung.  The tumor was continuously growing at multiple sites despite six surgical resections, radiotherapy, and two lines of systemic therapy.  Following detection of an AKT1E17K mutation in three independent tumor samples by sequencing, treatment with AZD5363, a selective AKT inhibitor, was initiated.  Ex vivo cultured meningioma cells exhibited sensitivity to the drug as shown by pAKT accumulation on immunoblots.  Treatment with AZD5363 resulted, for the first time, in stable disease and minor radiographic response.  The patient has been on that treatment for more than one year with ongoing clinical and radiographic response.  This is the first report of an AKT1-mutant meningioma responding to AKT inhibition, suggesting that molecular screening may result in clinical benefit.